Dexton Indications/Uses

Intramuscular or intravenous administration: Allergic states: For control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment; seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions; acute noninfectious laryngeal edema, urticarial transfusion reactions.
Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus or acute rheumatic carditis.
Dermatologic diseases: Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; exfoliative erythroderma; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis.
Edematous states: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that because of systemic lupus erythematosus.
Endocrine disorders: Primary, secondary, or acute adrenocortical insufficiency (hydrocortisone or cortisone is the first choice); preoperatively and in the event of serious trauma or illness, in adrenal insufficiency or when adrenocortical reserve is doubtful; septic shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected; congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in ulcerative colitis or regional enteritis.
Hematologic disorders: Immune thrombocytopenia in adults; secondary thrombocytopenia in adults (select cases); acquired (autoimmune) hemolytic anemia; pure red cell aplasia; congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia).
Neoplastic diseases: For palliative management of leukemias and lymphomas in adults and acute leukemia of childhood.
Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic diseases: In the severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis; keratitis; allergic corneal marginal ulcers; herpes zoster ophthalmicus; iritis and iridocyclitis; chorioretinitis; anterior segment inflammation; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; temporal arteritis; uveitis; ocular inflammatory conditions unresponsive to topical corticosteroids.
Respiratory diseases: Symptomatic sarcoidosis; Loeffler syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy; aspiration pneumonitis; idiopathic eosinophilic pneumonias.
Rheumatic disorders: For use as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis; treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
Intra-articular or soft tissue injection: For use as adjunctive therapy for short-term administration in synovitis or osteoarthritis, rheumatoid arthritis (RA), acute or subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis and post-traumatic osteoarthritis.
Intralesional injection: Keloids; localized hypertrophic infiltrated, inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; necrobiosis lipoidica diabeticorum; alopecia areata, cystic tumors of an aponeurosis or tendon (ganglia).